Pathway-based toxicity: History, current approaches and liver fibrosis and steatosis as prototypes

Altex

Volumn 31, Issue 4, 2014, Pages 407-421

  Willett, Catherine ^a   Rae, Jessica Caverly ^b   Goyak, Katy O ^c   Landesmann, Brigitte ^d   Minsavage, Gary ^c   Westmoreland, Carl ^e  

^a Humane Society of the United States   (United States)

^b DUPONT COMPANY   (United States)

^c EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^d JOINT RESEARCH CENTRE   (Italy)

^e UNILEVER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL COMPOUND; ESTROGEN RECEPTOR; INDUSTRIAL CHEMICAL; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PESTICIDE; TOXIC SUBSTANCE; DANGEROUS GOODS;

ADVERSE OUTCOME; ALKYLATION; BIOLOGY; CHEMICAL INTERACTION; CHOLESTASIS; CONFERENCE PAPER; DENDRITIC CELL; DOSE RESPONSE; DRUG INDUCED CANCER; DRUG MECHANISM; FATTY LIVER; HUMAN; LIVER FIBROSIS; LIVER GRANULOMA; LIVER METABOLISM; LIVER NECROSIS; LIVER TOXICITY; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR BINDING; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SKIN SENSITIZATION; STRUCTURE ACTIVITY RELATION; TOXIC HEPATITIS; TOXICITY TESTING; TOXICOLOGY; VASCULAR LESION; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; HISTORY; LIVER CIRRHOSIS; PREDICTIVE VALUE; TOXICITY; TRENDS;

ANIMALS; FATTY LIVER; HAZARDOUS SUBSTANCES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS; TOXICITY TESTS;

EID: 84926326815     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.1401283     Document Type: Conference Paper

References (51)

1. Aeby, P., Ashikaga, T., Bessou-Touya, S. et al. (2010). Identifying and characterizing chemical skin sensitizers without animal testing: Colipa's research and method development program. Toxicol In Vitro 24, 1465-1473. http://dx. doi. org/10. 1016/j. tiv. 2010. 07. 005
2. Andersen, M. (2012). A Research Plan for a Case Study Approach with Estrogen-Signaling to Accelerate Implementation of the 2007 NAS Report on Toxicity Testing. Research Trian gle Park: The Hamner Institutes for Health Sciences. http://www.thehamner. org/content/Tier-1-and-Done.pdf (accessed 19. 09. 2013)
3. Andersen, M., Clewell, R. and Bhattacharya, S. (2012). Developing in vitro tools sufficient by themselves for 21st century risk assessment. In T. Gocht and M. Schwarz, Towards Replacement of in vivo Repeated Dose Systemic Toxicity Testing. Vol. 2 (347-360). SEURAT-1 COACH Consortium
4. Andersen, M. E., McMullen, P. D. and Bhattacharya, S. (2013). Toxicogenomics for transcription factor-governed molecular pathways: moving on to roles beyond classification and prediction. Arch Toxicol 87, 7-11. http://dx. doi. org/10. 1007/s00204-012-0980-6
5. Ankley, G., Bennett, R., Erickson, R. et al. (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29, 730-741. http://dx. doi. org/10. 1002/etc. 34
6. Au, J., Navarro, V. and Rossi, S. (2011). Review article: drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 34, 11-20. http://dx. doi. org/10. 1111/j. 1365-2036. 2011. 04674. x
7. Bauch, C., Kolle, S., Fabian, E. et al. (2011). Intra-laboratory validation of four in vitro assays for the prediction of the skin sensitizing potential of chemicals. Toxicol In Vitro 25, 1162-1168. http://dx. doi. org/10. 1016/j. tiv. 2011. 05. 030
8. Boobis, A. R., Cohen, S. M., Dellarco, V. et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36, 781-792. http://dx. doi. org/10. 1080/10408440600977677
9. Boobis, A. R., Doe, J. E., Heinrich-Hirsch, B. et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38, 87-96. http://dx. doi. org/10. 1080/10408440701749421
10. Bradbury, S. P., Feijtel, T. C. and Van Leeuwen, C. J. (2004). Meeting the scientific needs of ecological risk assessment in a regulatory context. Environ Sci Technol 38, 463A-470A. http://dx. doi. org/10. 1021/es040675s
11. Bradford-Hill, A. (1965). The environment and disease: association or causation? Proc R Soc Med 58, 295-300
12. Carmichael, N., Bausen, M., Boobis, A. R. et al. (2011). Using mode of action information to improve regulatory decision making: an ECETOC/ILSI/HESI workshop overview. Crit Rev Toxicol 41, 175-186. http://dx. doi. org/10. 3109/10408444. 2010. 541225
13. Celander, M. C., Goldstone, J. V., Denslow, N. D. et al. (2011), Species extrapolation for the 21st century. Environ Toxicol Chem 30, 52-63. http://dx. doi. org/10. 1002/etc. 382
14. Clewell, H. J., Gentry, P. R., Gearheart, J. M. et al. (1995). Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. Chemosphere 31, 2561-2578. http://dx. doi. org/10. 1016/0045-6535(95)00124-Q
15. ECETOC-European Centre for Ecotoxicology and Toxicology of Chemicals (2007). Intelligent testing strategies in ecotoxicology: Mode of action approach for specifically acting chemicals. Technical Report 102, Brussels, Belgium
16. EC-European Commission (2013a). EURLECVAM Recom mendation on the Direct Peptide Reactivity Assay (DPRA) for Skin Sensitisation Testing. Institute for Health and Consumer Protection, Joint Research Centre, Ispra, Italy
17. EC (2013b). EURLECVAM Strategy for Replacement of Animal Testing for Skin Sensitisation Hazard Identification and Classification. Institute for Health and Consumer Protection, Joint Research Centre, Ispra, Italy
18. EC (2014). EURLECVAM Recommendation on the KeratinoSense for Skin Sensitisation Testing. Institute for Health and Consumer Protection, Joint Research Centre, Ispra, Italy
19. Goodman, Z. (2007). Neoplasms of the liver. Mod Pathol 20, S49-S60. http://dx. doi. org/10. 1038/modpathol. 3800682
20. Guengerich, F. (2008). Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21, 70-83. http://dx. doi. org/10. 1021/tx700079z
21. Holt, M. and Ju, C. (2006). Mechanisms of drug-induced liver injury. The AAPS J 8, E48-E54. http://dx. doi. org/10. 1208/aapsj080106
22. Iorio, F., Bosotti, R., Scacheri, E. et al. (2010). Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107, 14621-142626. http://dx. doi. org/10. 1073/pnas. 1000138107
23. Jaworska, J., Harol, A., Kern, P. S. and Gerberick, G. F. (2011). Integrating non-animal test information into an adaptive testing strategy-skin sensitization proof of concept case. ALTEX 28, 211-225. http://dx. doi. org/10. 14573/altex. 2011. 3. 211
24. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Disc 4, 489-499. http://dx. doi. org/10. 1038/nrd1750
25. Kleensang, A., Maertens, A., Rosenberg, M. et al. (2014). Pathways of Toxicity. ALTEX 31, 53-61. http://dx. doi. org/10. 14573/altex. 1309261
26. Kramer, V. J., Etterson, M. A., Hecker, M. et al. (2011). Adverse outcome pathways and ecological risk assessment: Bridging to population-level effects. Environ Toxicol Chem 30, 64-76. http://dx. doi. org/10. 1002/etc. 375
27. Lambrechts N, V. H., Witters, H., Van Den Heuvel, R. et al. (2010). Assessment of chemical skin sensitizing potency by an in vitro assay based on human dendritic cells. Toxicol Sci 116, 122-129. http://dx. doi. org/10. 1093/toxsci/kfq108
28. Landesmann, B., Goumenou, M., Munn, S. and Whelan, M. (2012). Description of Protoype Modes-of-action related to repeated dose toxicity. Ispra, Italy: European Commission, Joint Research Centre, JRC Scientific and Policy Report 75689. http://publications. jrc. ec. europa. eu/repository/handle/111111111/27015
29. McKim, J. J., Keller, D. and Gorski, J. (2012). An in vitro method for detecting chemical sensitization using human reconstructed skin models and its applicability to cosmetic, pharmaceutical, and medical device safety testing. Cutan Ocul Toxicol 31, 292-305. http://dx. doi. org/10. 3109/15569527. 2012. 667031
30. Meek, M., Bucher, J., Cohen, S. et al. (2003). A Framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33, 591-653. http://dx. doi. org/10. 1080/713608373
31. Meek, M. E., Boobis, A., Cote, I. et al. (2014). New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxi col 34, 1-18. http://dx. doi. org/10. 1002/jat. 2949
32. Natsch, A., Ryan, C. A., Foertsch, L. et al. (2013). A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. J Appl Toxicol 33, 1337-1352
33. NRC-National Research Council (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC, USA: National Academy of Sciences
34. Nichols, J. W., Breen, M., Denver, R. J. et al. (2011), Predicting chemical impacts on vertebrate endocrine systems. Environ Toxicol Chem 30, 39-51. http://dx. doi. org/10. 1002/etc. 376
35. OECD-Organization for Economic Coordination and Development (2008). Report of the Second Survey on Available Omics Tools. OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 100. ENV/JM/MONO(2008)35
36. OECD (2009). Report of the Expert Consultation to Evaluate an Estrogen Receptor Binding Affinity Model for Hazard Identification. Series on Testing and Assessment, No. 111. Paris: Organization for Economic Co-Operation and Development (OECD), Task Force on Hazard Assessment. http://search. oecd. org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282009%2933&doclanguage=en (accessed 19. 09. 2013)
37. OECD (2011). Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. Series on Testing and Assessment, No. 138. Paris: Organization for Economic Co-operation and Development (OECD). http://search. oecd. org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282011%298&doclanguage=en (accessed 19. 09. 2013)
38. OECD (2012). The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins, Part 1: Scientific Evidence. Series on Testing and Assessment, No. 168. Paris: Organisation for Economic Co-operation and Development (OECD). http://search. oecd. org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282012%2910/part1&doclanguage=en (accessed 19. 09. 2013)
39. OECD (2013). Guidance Document on Developing and Assessing Adverse Outcome Pathways. Series on Testing and Assessment, No. 184. Paris: Organization for Economic Co-operation and Development (OECD). http://search. oecd. org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282013%296&doclanguage=en (accessed 21. 05. 2014)
40. Perkins, E. J., Chipman, J. K., Edwards, S. et al. (2011). Reverse engineering adverse outcome pathways. Environ Toxicol Chem 30, 22-38. http://dx. doi. org/10. 1002/etc. 374
41. Parsons, T. (2011). CAATReceives $6 Million NIH Director's Grant to Pioneer Transformative Research in Toxicology Testing. Johns Hopkins Bloomburg School of Public Health: http://www.jhsph. edu/news/news-releases/2011/hartung-nih-award. html (accesssed 19. 09. 2013)
42. Rao, M. and Reddy, J. (2004). PPARa in the pathogenesis of fatty liver disease. Hepatology 40, 783-786. http://dx. doi. org/10. 1002/hep. 20453
43. Schadt, E. E. and Lum, P. Y. (2006). Reverse engineering gene networks to identify key drivers of complex disease pheno types. J Lipid Res 47, 2601-2613. http://dx. doi. org/10. 1194/jlr. R600026-JLR200
44. Schmieder, P. K., Tapper, M. A., Denny, J. S. et al. (2004). Use of trout liver slices to enhance mechanistic interpretation of estrogen receptor binding for cost-effective prioritization of chemicals within large inventories. Environ Sci Technol 38, 6333-6342. http://dx. doi. org/10. 1021/es0495314
45. US EPA-US Environmental Protection Agency (2006). Presentation to the 39th Joint Meeting of the Chemicals Committee and the Working Party on Chemicals: Experiences using integrated approaches to fulfill information requirements for Testing and Assessment. http://www.oecd. org/env/chemicalsafetyandbiosafety/36286164.pdf (accessed 19. 09. 2013)
46. US EPA (2007). Framework for Determining a Mutagenic Mode of action for Carcinogenicity: Using EPA's 2005 Cancer Guidelines and Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens. http://www.epa. gov/osa/mmoaframework/pdfs/MMOA-ERD-FINAL-83007.pdf (accessed 29. 12. 2013)
47. US EPA (2012). Prioritization of the Endocrine Disruptor Screening Program Universe of Chemicals for an Estrogen Receptor Adverse Outcome Pathway Using Computational Toxicology Tools. http://www.regulations. gov; docket number EPA-HQ-OPP-2012-0818 (accessed 15. 01. 2013)
48. US FDA-US Food and Drug Administration (2009). Guidance for industry-Drug-induce liver injury: premarketing clinical evaluation. Silver Springs: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, FDA. http://www.fda. gov/downloads/Drugs/... /Guidances/UCM174090.pdf (accessed 19. 09. 2013)
49. Villeneuve, D. and Garcia-Reyero, N. (2011). Vision & strategy: Predictive ecotoxicology in the 21st century. Environ Toxicol Chem 30, 1-8. http://dx. doi. org/10. 1002/etc. 396
50. Watanabe, K. H., Andersen, M. E., Basu, N. et al. (2011), Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study. Environ Toxicol Chem 30, 9-21. http://dx. doi. org/10. 1002/etc. 373
51. Willett, C., Caverly Rae, J., Goyak, K. O. et al. (2014). Building shared experience to advance practical application of pathway-based toxicology: Liver toxicity mode-of-action. ALTEX 31, 500-519. http://dx. doi. org/10. 14573/altex. 1401281